133 related articles for article (PubMed ID: 37421290)
21. Identification of an EMT-related gene-based prognostic signature in osteosarcoma.
Gong H; Tao Y; Xiao S; Li X; Fang K; Wen J; Zeng M; Liu Y; Chen Y
Cancer Med; 2023 Jun; 12(11):12912-12928. PubMed ID: 37102261
[TBL] [Abstract][Full Text] [Related]
22. Construction of a Necroptosis-Associated Long Non-Coding RNA Signature to Predict Prognosis and Immune Response in Hepatocellular Carcinoma.
Wang W; Ye Y; Zhang X; Ye X; Liu C; Bao L
Front Mol Biosci; 2022; 9():937979. PubMed ID: 35911976
[No Abstract] [Full Text] [Related]
23. Identification and validation of the necroptosis-related gene signature related to prognosis and tumor immune in hepatocellular carcinoma.
Xiang Z; Mranda GM; Zhou X; Xue Y; Wang Y; Wei T; Liu J; Ding Y
Medicine (Baltimore); 2022 Sep; 101(36):e30219. PubMed ID: 36086716
[TBL] [Abstract][Full Text] [Related]
24. Identification of 6 gene markers for survival prediction in osteosarcoma cases based on multi-omics analysis.
Li R; Wang G; Wu Z; Lu H; Li G; Sun Q; Cai M
Exp Biol Med (Maywood); 2021 Jul; 246(13):1512-1523. PubMed ID: 33563042
[TBL] [Abstract][Full Text] [Related]
25. C-C Motif Chemokine Ligand 5 (CCL5): A Potential Biomarker and Immunotherapy Target for Osteosarcoma.
Zheng H; Wang Y; Li F
Curr Cancer Drug Targets; 2024; 24(3):308-318. PubMed ID: 37581517
[TBL] [Abstract][Full Text] [Related]
26. Necrotizing apoptosis-related genes prognosis and treatment effect analysis of osteosarcoma in children.
Chen Y; Wu L; Li Y; Zheng J; Zhong S; Gu S; Chen J
J Gene Med; 2024 Jan; 26(1):e3646. PubMed ID: 38100138
[TBL] [Abstract][Full Text] [Related]
27. A novel model based on necroptosis to assess progression for polycystic ovary syndrome and identification of potential therapeutic drugs.
Wang M; An K; Huang J; Mprah R; Ding H
Front Endocrinol (Lausanne); 2023; 14():1193992. PubMed ID: 37745699
[TBL] [Abstract][Full Text] [Related]
28. Identification of UBE2I as a Novel Biomarker in ccRCC Based on a Large-Scale CRISPR-Cas9 Screening Database and Immunohistochemistry.
Li F; Lai L; You Z; Cheng H; Guo G; Tang C; Xu L; Liu H; Zhong W; Lin Y; Wang Q; Lin Y; Wei Y
Front Mol Biosci; 2022; 9():813428. PubMed ID: 35211510
[No Abstract] [Full Text] [Related]
29. Construction of a 5-gene prognostic signature based on oxidative stress related genes for predicting prognosis in osteosarcoma.
Hong X; Fu R
PLoS One; 2023; 18(12):e0295364. PubMed ID: 38039294
[TBL] [Abstract][Full Text] [Related]
30. A multi-omics-based investigation of the prognostic and immunological impact of necroptosis-related mRNA in patients with cervical squamous carcinoma and adenocarcinoma.
Zou J; Lin Z; Jiao W; Chen J; Lin L; Zhang F; Zhang X; Zhao J
Sci Rep; 2022 Oct; 12(1):16773. PubMed ID: 36202899
[TBL] [Abstract][Full Text] [Related]
31. N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma.
Yang K; Wang F; Li K; Peng G; Yang H; Xu H; Xiang Y; Sun H
Technol Cancer Res Treat; 2022; 21():15330338221085354. PubMed ID: 35422168
[No Abstract] [Full Text] [Related]
32. Construction of a Five-Super-Enhancer-Associated-Genes Prognostic Model for Osteosarcoma Patients.
Ouyang Z; Li G; Zhu H; Wang J; Qi T; Qu Q; Tu C; Qu J; Lu Q
Front Cell Dev Biol; 2020; 8():598660. PubMed ID: 33195283
[TBL] [Abstract][Full Text] [Related]
33. The hexosamine biosynthesis pathway-related gene signature correlates with immune infiltration and predicts prognosis of patients with osteosarcoma.
Su Z; Wang C; Pan R; Li H; Chen J; Tan J; Tian X; Lin T; Shen J
Front Immunol; 2022; 13():1028263. PubMed ID: 36275679
[TBL] [Abstract][Full Text] [Related]
34. Development of a novel vasculogenic mimicry-associated gene signature for the prognostic assessment of osteosarcoma patients.
Yan L; Li R; Li D; Zhu Y; Lv Z; Wang B
Clin Transl Oncol; 2023 Dec; 25(12):3501-3518. PubMed ID: 37219824
[TBL] [Abstract][Full Text] [Related]
35. Development of an immune-related prognostic index associated with osteosarcoma.
Yin CD; Hou YL; Liu XR; He YS; Wang XP; Li CJ; Tan XH; Liu J
Bioengineered; 2021 Dec; 12(1):172-182. PubMed ID: 33371790
[TBL] [Abstract][Full Text] [Related]
36. Deciphering a Novel Necroptosis-Related miRNA Signature for Predicting the Prognosis of Clear Cell Renal Carcinoma.
Bao JH; Li JB; Lin HS; Zhang WJ; Guo BY; Li JJ; Fu LM; Sun YP
Anal Cell Pathol (Amst); 2022; 2022():2721005. PubMed ID: 35509814
[TBL] [Abstract][Full Text] [Related]
37. Construction of a novel necroptosis-related lncRNA signature for prognosis prediction in esophageal cancer.
Liu Y; Hao H; Kang L; Zheng G; Guo X; Li B; Zhao H; Hao H
BMC Gastroenterol; 2022 Jul; 22(1):345. PubMed ID: 35840890
[TBL] [Abstract][Full Text] [Related]
38. Identification of necroptosis-related long non-coding RNAs prognostic signature and the crucial lncRNA in bladder cancer.
Sun YF; Chen L; Xia QJ; Wang TH
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10217-10234. PubMed ID: 37269345
[TBL] [Abstract][Full Text] [Related]
39. SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma.
Guo T; Wei R; Dean DC; Hornicek FJ; Duan Z
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34984436
[TBL] [Abstract][Full Text] [Related]
40. Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors.
Liu W; Wang S; Lin B; Zhang W; Ji G
BMC Musculoskelet Disord; 2021 Feb; 22(1):149. PubMed ID: 33546657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
